{
    "clinical_study": {
        "@rank": "74142", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and antiviral HBV activity of ACH126,\n      433 (b-L-Fd4C) in the treatment of adults with lamivudine-resistant chronic Hepatitis B."
        }, 
        "brief_title": "Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B", 
        "completion_date": {
            "#text": "May 2003", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Hepatitis B", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Evaluation of safety and antiviral activity of 3 dose levels of ACH126, 443 over a twelve\n      week treatment in the population described."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Adults \u2265 18 years of age\n\n          -  Chronic HBV infection, known to be HbsAg positive \u2265 6 months\n\n          -  On lamivudine, either 100 or 150 mg daily for the treatment of chronic hepatitis B\n             infection and\n\n          -  Exhibit a 2-3 log decrease in HBV DNA levels followed by a rebound of at least 1.5\n             log HBV DNA or\n\n               -  Achieved an HBV DNA level of <10,000 copies/mL HBV DNA on at least 2 occasions\n                  and have rebounded to > 100,000 copies/mL HBV DNA, or\n\n               -  Have a demonstrable 3TC resistant genotype regardless of treatment history.\n\n          -  HBeAG positive\n\n          -  HIV negative\n\n          -  Serum ALT \u22651.5 and \u226410x times upper limit of normal\n\n          -  HGB \u226510g/dl or HCT \u226530% (in the absence of blood transfusions or erythropoietin\n             treatment in the preceding two weeks)\n\n          -  Platelet count >75,000/mm(^3), (in the absence of ongoing G-CSF therapy)\n\n          -  Serum creatinine <1.1 times upper limit of normal (ULN)\n\n          -  Negative radiologic screening test (ultrasound, CT scan or MRI) for hepatocellular\n             carcinoma (HCC) within 6 months prior to entry\n\n          -  PT/INR<2\n\n          -  Subjects of reproductive capability must utilize an approved forms of birth control\n\n          -  All women of child-bearing capability must have a negative serum or urine pregnancy\n             test (minimum sensitivity of 24 IU/L of b-HCG) within 72 hours prior to the start of\n             study medication\n\n          -  Subjects must be able to provide written informed consent\n\n          -  Subject must be available for follow-up for a period of 20 weeks\n\n        Exclusion Criteria\n\n          -  HIV infection\n\n          -  Hepatitis C co-infection\n\n          -  Alcohol abuse\n\n          -  Pregnancy or breast-feeding\n\n          -  Inability to tolerate oral medication\n\n          -  Any clinical condition or prior therapy that, in the Investigator's opinion, would\n             make the subject unsuitable for the study or unable to comply with the dosing\n             requirements\n\n          -  Use of any investigational drug\n\n          -  Patients with decompensated liver disease\n\n          -  Use of any concomitant herbal treatments"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "85", 
        "firstreceived_date": "June 21, 2002", 
        "id_info": {
            "nct_id": "NCT00040144", 
            "org_study_id": "ACH443-005"
        }, 
        "intervention": {
            "intervention_name": "ACH126, 433 (b-L-Fd4C)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Lamivudine"
        }, 
        "keyword": [
            "E-Antigen positive,", 
            "Lamivudine-Resistant Chronic Hepatitis B,", 
            "Achillion"
        ], 
        "lastchanged_date": "August 18, 2009", 
        "link": {
            "url": "http://www.achillion.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90048"
                    }, 
                    "name": "Cedars Sinai Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92868"
                    }, 
                    "name": "University of California-Irvine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pasadena", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91105"
                    }, 
                    "name": "Huntington Memorial Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143-0538"
                    }, 
                    "name": "University of California-San Francisco"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "University of Miami"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "University of Chicago"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612-7323"
                    }, 
                    "name": "University of Illinois at Chicago"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Beth Israel Deaconess Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Cornell Weill Medical College"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75390"
                    }, 
                    "name": "The University of Texas"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }, 
                    "name": "Baylor Universtiy Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }, 
                    "name": "Southwest Infectious Disease Associates, P.A."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fairfax", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22031"
                    }, 
                    "name": "Metropolitan Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98195"
                    }, 
                    "name": "Unviversity of Washington"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V5Z 1L5"
                    }, 
                    "name": "Vancouver General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2C4"
                    }, 
                    "name": "Toronto General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5T 2S8"
                    }, 
                    "name": "Toronto Western Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2X 3J4"
                    }, 
                    "name": "University of Montreal"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hong Kong SAR", 
                        "country": "China"
                    }, 
                    "name": "The University of Hong Kong"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "China"
            ]
        }, 
        "official_title": "A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of 12 Weeks Oral Treatment With ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00040144"
        }, 
        "source": "Achillion Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Achillion Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2009", 
        "why_stopped": "Safety concerns"
    }, 
    "geocoordinates": {
        "Baylor Universtiy Medical Center": "32.803 -96.77", 
        "Beth Israel Deaconess Medical Center": "42.358 -71.06", 
        "Cedars Sinai Medical Center": "34.052 -118.244", 
        "Cornell Weill Medical College": "40.714 -74.006", 
        "Huntington Memorial Hospital": "34.148 -118.145", 
        "Metropolitan Research": "38.846 -77.306", 
        "Southwest Infectious Disease Associates, P.A.": "32.803 -96.77", 
        "The University of Hong Kong": "22.396 114.109", 
        "The University of Texas": "32.803 -96.77", 
        "Toronto General Hospital": "43.653 -79.383", 
        "Toronto Western Hospital": "43.653 -79.383", 
        "University of California-Irvine": "33.788 -117.853", 
        "University of California-San Francisco": "37.775 -122.419", 
        "University of Chicago": "41.878 -87.63", 
        "University of Illinois at Chicago": "41.878 -87.63", 
        "University of Miami": "25.789 -80.226", 
        "University of Montreal": "45.509 -73.554", 
        "Unviversity of Washington": "47.606 -122.332", 
        "Vancouver General Hospital": "49.261 -123.114"
    }
}